D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 118 Citations 71,540 682 World Ranking 1710 National Ranking 66

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Surgery
  • Disease

His primary areas of study are Internal medicine, Surgery, Placebo, Crohn's disease and Gastroenterology. His Ulcerative colitis, Inflammatory bowel disease, Adverse effect, Infliximab and Maintenance therapy investigations are all subjects of Internal medicine research. Within one scientific family, Brian G. Feagan focuses on topics pertaining to Etrolizumab under Surgery, and may sometimes address concerns connected to Phases of clinical research.

Brian G. Feagan has researched Placebo in several fields, including Clinical endpoint, Randomized controlled trial, Clinical trial and Induction chemotherapy. His work focuses on many connections between Crohn's disease and other disciplines, such as Severity of illness, that overlap with his field of interest in Visual analogue scale and Pathology. The Gastroenterology study combines topics in areas such as Pharmacokinetics, Vedolizumab, Crohn's Disease Activity Index, Gastrointestinal agent and C-reactive protein.

His most cited work include:

  • Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial (3357 citations)
  • Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis (2790 citations)
  • Infliximab Maintenance Therapy for Fistulizing Crohn's Disease (1693 citations)

What are the main themes of his work throughout his whole career to date?

His main research concerns Internal medicine, Gastroenterology, Crohn's disease, Ulcerative colitis and Inflammatory bowel disease. His Internal medicine research includes elements of Placebo and Surgery. His research integrates issues of Adverse effect, Randomized controlled trial and Maintenance therapy in his study of Placebo.

His Crohn's disease study integrates concerns from other disciplines, such as Physical therapy, Clinical trial, Certolizumab pegol and Ustekinumab. His study in Ulcerative colitis is interdisciplinary in nature, drawing from both Colitis and Adalimumab, Golimumab, Infliximab. His studies deal with areas such as Gastrointestinal agent, Quality of life, Immunology and Intensive care medicine as well as Inflammatory bowel disease.

He most often published in these fields:

  • Internal medicine (76.05%)
  • Gastroenterology (43.15%)
  • Crohn's disease (41.21%)

What were the highlights of his more recent work (between 2017-2021)?

  • Internal medicine (76.05%)
  • Ulcerative colitis (37.00%)
  • Gastroenterology (43.15%)

In recent papers he was focusing on the following fields of study:

Internal medicine, Ulcerative colitis, Gastroenterology, Crohn's disease and Inflammatory bowel disease are his primary areas of study. Brian G. Feagan regularly ties together related areas like Placebo in his Internal medicine studies. Brian G. Feagan has included themes like Meta-analysis, Randomized controlled trial and Maintenance therapy in his Placebo study.

His research investigates the link between Ulcerative colitis and topics such as Confidence interval that cross with problems in Odds ratio. His Gastroenterology research incorporates elements of Clinical endpoint, Induction therapy, Calprotectin and Ozanimod. Brian G. Feagan works mostly in the field of Crohn's disease, limiting it down to topics relating to Post-hoc analysis and, in certain cases, Immunosuppression, as a part of the same area of interest.

Between 2017 and 2021, his most popular works were:

  • Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease. (79 citations)
  • Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy. (63 citations)
  • Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn’s Disease (62 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Disease
  • Cancer

Brian G. Feagan mostly deals with Internal medicine, Crohn's disease, Ulcerative colitis, Placebo and Gastroenterology. His study in Randomized controlled trial, Vedolizumab, Clinical trial, Adverse effect and Crohn's Disease Activity Index falls under the purview of Internal medicine. His biological study spans a wide range of topics, including Hazard ratio, Prospective cohort study, Radiology and C-reactive protein.

His Ulcerative colitis research includes themes of Odds ratio, Tofacitinib, Colitis, Inflammatory bowel disease and Receiver operating characteristic. The various areas that Brian G. Feagan examines in his Placebo study include Infliximab, Ustekinumab, Confidence interval, Meta-analysis and Endoscopy. His Gastroenterology study combines topics from a wide range of disciplines, such as Biomarker, Clinical endpoint, Maintenance therapy and Phases of clinical research.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

Stephen B Hanauer;Brian G Feagan;Gary R Lichtenstein;Lloyd F Mayer.
The Lancet (2002)

4780 Citations

Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis

Paul Rutgeerts;William J Sandborn;Brian G Feagan;Walter Reinisch.
The New England Journal of Medicine (2005)

3902 Citations

Infliximab Maintenance Therapy for Fistulizing Crohn's Disease

Bruce E. Sands;Frank H. Anderson;Charles N. Bernstein;William Y. Chey.
The New England Journal of Medicine (2004)

2385 Citations

Vedolizumab as induction and maintenance therapy for ulcerative colitis.

Brian G Feagan;Paul Rutgeerts;Bruce E Sands;Stephen Hanauer.
The New England Journal of Medicine (2013)

1794 Citations

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

William J. Sandborn;Brian G. Feagan;Paul Rutgeerts;Stephen Hanauer.
The New England Journal of Medicine (2013)

1648 Citations

Certolizumab pegol for the treatment of Crohn’s disease:

William J. Sandborn;Brian G. Feagan;Simeon Stoinov;Pieter J. Honiball.
The New England Journal of Medicine (2007)

1421 Citations

A Review of Activity Indices and Efficacy End Points for Clinical Trials of Medical Therapy in Adults With Ulcerative Colitis

Geert D’Haens;William J. Sandborn;Brian G. Feagan;Karel Geboes.
Gastroenterology (2007)

1312 Citations

Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial

Geert D'Haens;Filip Baert;Gert van Assche;Philip Caenepeel.
The Lancet (2008)

1258 Citations

Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease.

Paul Rutgeerts;Brian G. Feagan;Gary R. Lichtenstein;Lloyd F. Mayer.
Gastroenterology (2004)

1163 Citations

Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.

L. Peyrin-Biroulet;W. Sandborn;B. E. Sands;W. Reinisch;W. Reinisch.
The American Journal of Gastroenterology (2015)

1122 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Brian G. Feagan

Laurent Peyrin-Biroulet

Laurent Peyrin-Biroulet

University of Lorraine

Publications: 388

William J. Sandborn

William J. Sandborn

University of California, San Diego

Publications: 342

Severine Vermeire

Severine Vermeire

KU Leuven

Publications: 288

Silvio Danese

Silvio Danese

Humanitas University

Publications: 262

Jean-Frederic Colombel

Jean-Frederic Colombel

Icahn School of Medicine at Mount Sinai

Publications: 259

Paul Rutgeerts

Paul Rutgeerts

KU Leuven

Publications: 199

Stephen B. Hanauer

Stephen B. Hanauer

Northwestern University

Publications: 171

Walter Reinisch

Walter Reinisch

Medical University of Vienna

Publications: 160

Edward V. Loftus

Edward V. Loftus

Mayo Clinic

Publications: 159

Peter L. Lakatos

Peter L. Lakatos

McGill University

Publications: 158

Gert Van Assche

Gert Van Assche

KU Leuven

Publications: 156

Remo Panaccione

Remo Panaccione

University of Calgary

Publications: 152

Javier P. Gisbert

Javier P. Gisbert

Autonomous University of Madrid

Publications: 148

Subrata Ghosh

Subrata Ghosh

University College Cork

Publications: 146

Gary R. Lichtenstein

Gary R. Lichtenstein

University of Pennsylvania

Publications: 139

Geert R. D'Haens

Geert R. D'Haens

University of Amsterdam

Publications: 136

Trending Scientists

Kadangode K. Ramakrishnan

Kadangode K. Ramakrishnan

University of California, Riverside

Cristian S. Calude

Cristian S. Calude

University of Auckland

Jue Wang

Jue Wang

Tencent (China)

Waqar Azeem Khan

Waqar Azeem Khan

Prince Mohammad bin Fahd University

Dan M. Ionel

Dan M. Ionel

University of Kentucky

Metin Akay

Metin Akay

University of Houston

Richard S. Stein

Richard S. Stein

University of Massachusetts Amherst

Thomas D. Brock

Thomas D. Brock

University of Wisconsin–Madison

Peter Malin

Peter Malin

University of Auckland

Anthony D. Kelleher

Anthony D. Kelleher

UNSW Sydney

David M. Murray

David M. Murray

National Institutes of Health

Shahrokh F. Shariat

Shahrokh F. Shariat

Medical University of Vienna

Elizabeth Murray

Elizabeth Murray

University College London

Serge Hercberg

Serge Hercberg

Université Paris Cité

William I. Bensinger

William I. Bensinger

Fred Hutchinson Cancer Research Center

Ronald J. Faber

Ronald J. Faber

University of Minnesota

Something went wrong. Please try again later.